Electronic Supplementary Material (ESI) for Dalton Transactions

Supporting Information

Mangiferin Functionalized Radioactive Gold Nanoparticles (MGF-198AuNPs) in Prostate Tumor Therapy: Green Nanotechnology of Production, In Vivo Tumor Retention and Evaluation of Therapeutic Efficacy

A. Y. Al-Yasiri,* a M. Khoobchandani, b C. S. Cutler, c L. Watkinson, d T. Carmack, d C. J. Smith, e M. Kuchuk, f S. K. Loyalka, a* A. B. Lugão, g and K. V. Katti, h*

a Nuclear Science and Engineering Institute (NSEI), University of Missouri, Columbia, MO 65211, USA
b Department of Radiology, Institute of Green Nanotechnology, University of Missouri, One Hospital Drive, Columbia, MO, 65212, USA
c Nuclear Science and Engineering Institute (NSEI), University of Missouri Research Reactor (MURR), University of Missouri, Columbia, MO 65211, USA
d Harry S. Truman Memorial Veterans Hospital, University of Missouri, One Hospital Drive, Columbia, MO, 65212, USA
e Department of Radiology, Harry S. Truman Memorial Veterans Hospital, University of Missouri, One Hospital Drive, Columbia, MO, 65212, USA
f University of Missouri Research Reactor (MURR), University of Missouri, One Hospital Drive, Columbia, MO, 65212, USA
g Nuclear and Energy Research Institute – IPEN/CNEN/Sao Paulo, Brazil
h Nuclear Science and Engineering Institute (NSEI), Department of Radiology, Institute of Green Nanotechnology, University of Missouri Research Reactor (MURR), Harry S. Truman Memorial Veterans Hospital, Department of Physics, University of Missouri, One Hospital Drive, Columbia, MO, 65212, USA
Email: LoyalkaS@missouri.edu, kattik@health.missouri.edu

Therapeutic effect of MGF-198AuNPs and their effect on animal health

The results from antitumor studies demonstrate that the radioactive MGF-198AuNPs have significant therapeutic effects as reflected in their ability to control and reduce the tumor volume in comparison to control groups during three weeks of treatment. Animals were monitored for their body weight to measure the toxic effect of MGF-198AuNPs. As shown in figure SI1A, bodyweight change curves indicate that MGF-198AuNPs did not show any toxic effect on animal body weight. The overall body weight of treated groups of animals remained comparable with those of healthy normal control group. However, untreated control set of prostate tumor bearing animals showed significant reduction in the body weight by the end of the experiment (Figure SI 1A). These results indicate that MGF-198AuNPs did not show any adverse toxic effects on animal health. It should be noted that, in the untreated control group of animals, due to the severe body weight loss and excess tumor growth, few animals were sacrificed. Therefore, 33.33% saline treated tumor bearing mice were left at the end of the last day of in vivo investigations (Figure SI 1B). However, in the MGF-198AuNPs treated group, 50% animals survived till 24 days (Figure SI 1B). The results together corroborate that MGF-198AuNPs inhibit the growth of tumor without any adverse effects.

Evaluation of radiotoxicity of MGF-198AuNPs in blood samples of treated and untreated mice

In order to evaluate potential radiotoxicity effects post treatment with MGF-198AuNPs, we have analyzed blood parameters of treated animals and compared with the control group which were not treated and not inoculated with tumor cells, and was assigned as the 4th group with baseline levels of SCID mice that had not been experimentally manipulated and served as control for this analysis. Comparisons included mean counts for white cells, red cells, lymphocytes, and platelets counts (Figure SI 2). The analysis showed that the mean white blood cell (WBC) count for MGF-198AuNPs-treated groups was 2.96±0.88×10^3 WBC/µL, and for saline treated group was 3.56±2.04×10^3 WBC/µL. These data have revealed that (WBC) count in MGF-198AuNPs-treated groups was slightly lower than (WBC) count in the normal control group.

Red blood cells count (RBCs) in MGF-198AuNPs-treated group and control saline treated group was 11.97×10^6±0.7 /µL and 11.73×10^6±1.6 /µL respectively. The results indicated that the mean RBC count in treated group was slightly higher than RBC count in the normal control group (10.81×10^6±0.31/µL). The lymphocytes count was found to be 0.57×10^3±0.22/µL in MGF-198AuNPs-treated group and 0.52×10^3±0.27/µL in saline treated group. The lymphocytes count was found similar in both groups and in the normal control group (0.66×10^3±0.25). Furthermore, the platelet counts for MGF-198AuNPs treated groups was 1098±327×10^3/µL, and for the saline treated group was 981±260×10^3/µL. Platelets count for normal control group was 741±293 10^3/µL. It can be observed that the platelets count for both treatment groups was higher than for the
normal control group. Overall, detailed analysis on blood parameters as outlined above have demonstrated MGF-^{198}AuNPs treatment did not cause any adverse radiotoxicity throughout the course of treatment regimen.

**Control experiment for therapeutic study**
The effect of radioactive MGF-^{198}AuNPs showed compelling evidence on the reduction of human prostate tumor in SCID mice. The biodistribution and tumor retention time point studies indicate the stability and tumor specificity of MGF-^{198}AuNPs. However, it was important to compare the antitumor efficacy with MGF alone to prove the effective and selective antitumor efficacy of MGF-^{198}AuNPs. Therefore, separate experiment was performed to evaluate the effect of MGF on human prostate tumor bearing SCID mice. PC-3 cells were inoculated into SCID mice and were allowed to grow prostate tumor for 3-4 weeks. Animals were monitored under experimental conditions for their body weight and tumor volume. After three weeks, animals were randomized based on their average tumor volume and body weight; and divided into two groups: group 1 saline treated and group 2 MGF treated. Mice were given single dose: group1 (saline 30µL) and group 2 (MGF 5.8 µg/30µL) intratumorally and were kept for another 3-4 weeks to monitor their tumor volume and body weight. The MGF dose was calculated and selected based on the amount of MGF present in the MGF-^{198}AuNPs. Mice were sacrificed at the end of the study. The results presented in the figure SI 3 suggest that the tumor volume in the MGF treated group was smaller (0.12 cm\(^3\)) than the untreated control group (0.15 cm\(^3\)) on day 10. However, the tumor volumes appear to increase in the MGF treated (0.4 cm\(^3\) on day 24\(^{th}\)) and untreated control groups (0.44 cm\(^3\) on day 17\(^{th}\)). The results suggest that MGF alone does improve the life span of the animal but it does not inhibit the tumor growth. Therefore, the results from these control experiments suggest that MGF functionalized radioactive gold nanoparticles have definitive and selective antitumor efficacy in human prostate tumor induced SCID mice. These studies corroborate the importance of selectivity of MGF-^{198}AuNPs towards Lam-67R receptors which are overexpressed in prostate tumor cells and the overall therapeutic efficacy of this new radioactive mangiferin functionalized gold nanoparticulate.

**Conjugation efficiency- Determination of number of MGF per nanoparticle:** We have followed procedures reported in the literature for the calculation of conjugation efficacy of Mangiferin around gold nanoparticles. The concentration of MGF in MGF-AuNPs, as calculated by UV-visible spectrophotometry, was found to be 173 µg/mL. The number of MGF moles per ml is 2.463x10^{17}. Further, the number of MGF molecules per NPs was calculated using the[1, 2]-

\[
\text{MGF per nanoparticles} = \frac{\text{Number of MGF per ml}}{\text{number of NPs per ml}} = \frac{2.463x10^{17}}{7.27368x10^{11}} = 338617.7463
\]

Therefore, using the above calculation, we have confirmed that the average number of Mangiferin molecules per nanoparticle to be 338618.
Figure SI 1. (A) Effect of MGF-198AuNPs on body weight of SCID mice after a single dose intra tumoral administration in human prostate cancer bearing SCID mice (mean±SD). (B) Percent survival of mice after treatment with MGF-198AuNPs and comparison with untreated control mice; N=5±SD.
Figure SI 2. Comparison of blood parameters including (A) white blood cells, (B) red blood cells, (C) platelets, and (D) lymphocytes counts between the treatment and control groups with baseline levels obtained from a group of SCID mice that received no manipulations (normal control); N=5.
**Figure SI 3.** Therapeutic efficacy studies of free MGF after a single dose intra tumoral administration in human prostate cancer bearing SCID mice (N=5±SD). The therapeutic effect was maintained over a three weeks period.
References:


2. X. O. Liu, M. Atwater, J. H. Wang and Q. Huo, Extinction coefficient of gold nanoparticles with different sizes and different capping ligands. *Colloid Surface B*. 2007;58:3-7